Senaparib for epithelial ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how well the drug senaparib works for people with certain types of ovarian cancer (including fallopian tube and peritoneal cancers). It may help doctors understand better ways to treat these cancers using this targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- You must be at least 18 years old.
- Your doctor must agree that you can take the study drug (senaparib) either alone or with other treatments.
- If you could become pregnant, you must use effective birth control during the study and for 90 days after your last dose.
- You cannot be pregnant or breastfeeding.
- You cannot be in another research study that gives extra treatments beyond regular care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two drugs, senaparib and bevacizumab, after initial chemotherapy can help keep advanced ovarian cancer from coming back. It is for patients whose tumors are homologous recombination proficient (HRP), meaning their cancer cells are better at repairing DNA, and who have responded well to their first platinum-based treatment.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This trial tests a combination of two drugs, senaparib and temozolomide, for women with a specific type of ovarian cancer that has come back or is resistant to platinum-based chemotherapy. It is for patients whose tumor has a change in the ARID1A gene.
This trial tests a combination of two targeted drugs, niraparib and abemaciclib, for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back after at least two prior chemotherapies. It may be an option if you have no standard treatments left and your cancer still responds to platinum-based chemotherapy.
Hear when a new Ovarian Cancer (OvCa) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.